
AVXL Stock Forecast & Price Target
AVXL Analyst Ratings
Bulls say
Anavex Life Sciences is well-positioned for growth with a strategic reset in the EU following negative feedback from the EMA, while pursuing ongoing regulatory engagement in the US. They have also submitted additional data to the FDA and are actively working to address CHMP feedback to strengthen their data package. Their multi-indication potential for drugs like ANAVEX 2-73 in markets like Alzheimer's, Rett Syndrome, and Parkinson's Disease Dementia gives them a wide range of possibilities for growth, and their lower probability of success in therapeutic models in the US (50%) and EU (15%) further supports their potential.
Bears say
Anavex Life Sciences is facing a negative outlook due to several factors. The company's pipeline of drugs under development for various CNS diseases has a high risk of failure and limited potential for success. Additionally, the company's financials are not strong, with a high discount rate and low probability of success in its therapeutic models, making it a risky investment. Furthermore, while the company's latest update on correlation analyses and subgroup framing is supportive, it is not a new registrational outcome or regulatory event, highlighting the company's lack of significant progress.
This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
AVXL Analyst Forecast & Price Prediction
Start investing in AVXL
Order type
Buy in
Order amount
Est. shares
0 shares